Profund Advisors LLC lessened its position in shares of Cambrex Corporation (NYSE:CBM) by 4.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,786 shares of the biotechnology company’s stock after selling 290 shares during the period. Profund Advisors LLC’s holdings in Cambrex Corporation were worth $346,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Amalgamated Bank grew its holdings in Cambrex Corporation by 6.1% during the 2nd quarter. Amalgamated Bank now owns 4,473 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 258 shares in the last quarter. BlackRock Inc. grew its holdings in Cambrex Corporation by 0.5% during the 2nd quarter. BlackRock Inc. now owns 4,023,607 shares of the biotechnology company’s stock worth $240,409,000 after acquiring an additional 20,652 shares in the last quarter. Nationwide Fund Advisors grew its holdings in Cambrex Corporation by 3.1% during the 2nd quarter. Nationwide Fund Advisors now owns 178,016 shares of the biotechnology company’s stock worth $10,636,000 after acquiring an additional 5,275 shares in the last quarter. King Luther Capital Management Corp grew its holdings in Cambrex Corporation by 11.2% during the 2nd quarter. King Luther Capital Management Corp now owns 70,865 shares of the biotechnology company’s stock worth $4,234,000 after acquiring an additional 7,146 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in Cambrex Corporation by 18.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 296,181 shares of the biotechnology company’s stock worth $17,697,000 after acquiring an additional 45,742 shares in the last quarter. Institutional investors own 98.28% of the company’s stock.

Several research analysts have commented on CBM shares. BidaskClub upgraded shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a report on Friday, August 4th. ValuEngine upgraded shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a report on Tuesday, August 22nd. Finally, Zacks Investment Research cut shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $65.67.

In other news, CEO Steven M. Klosk sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $51.53, for a total transaction of $618,360.00. Following the completion of the sale, the chief executive officer now owns 95,328 shares of the company’s stock, valued at $4,912,251.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven M. Klosk sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $54.96, for a total transaction of $219,840.00. Following the sale, the chief executive officer now directly owns 87,328 shares of the company’s stock, valued at approximately $4,799,546.88. The disclosure for this sale can be found here. Insiders have sold 28,000 shares of company stock valued at $1,574,880 in the last three months. Corporate insiders own 2.48% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/07/profund-advisors-llc-has-346000-holdings-in-cambrex-corporation-cbm.html.

Shares of Cambrex Corporation (CBM) opened at 56.30 on Friday. The stock’s 50 day moving average is $52.80 and its 200 day moving average is $55.36. Cambrex Corporation has a 12 month low of $38.30 and a 12 month high of $62.95. The stock has a market cap of $1.84 billion, a P/E ratio of 20.51 and a beta of 2.28.

Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.76. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The company had revenue of $134.55 million during the quarter, compared to the consensus estimate of $136.82 million. During the same quarter last year, the company earned $0.68 earnings per share. Cambrex Corporation’s revenue for the quarter was up 13.4% on a year-over-year basis. Analysts predict that Cambrex Corporation will post $3.08 earnings per share for the current fiscal year.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Stock Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related stocks with our FREE daily email newsletter.